Gene therapy progress and prospects: Non-viral gene therapy by systemic delivery

Gene Therapy

Volumn 13, Issue 18, 2006, Pages 1313-1319

  Li, S D ^a   Huang, L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATELOCOLLAGEN; DRUG CARRIER; DYSTROPHIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; INSULIN ANTIBODY; INTERLEUKIN 2; LIPOPLEX; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; NAKED DNA; NANOPARTICLE; OLIGONUCLEOTIDE; PLASMID DNA; POLOXAMER; PROTAMINE; SMALL INTERFERING RNA; TRANSFERRIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BONE METASTASIS; CANCER THERAPY; CLINICAL TRIAL; DUCHENNE MUSCULAR DYSTROPHY; ENCAPSULATION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; IMMUNOTOXICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA INTERFERENCE; SAFETY; SCALE UP;

DNA; FORECASTING; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS; LIPOSOMES; NEOPLASMS; RNA INTERFERENCE; TRANSFECTION;

EID: 33748290173     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302838     Document Type: Review

References (39)

1. Roth CM, Sundaram S. Engineering synthetic vectors for improved DNA delivery: Insights from intracellular pathways. Annu Rev Biomed Eng 2004; 6: 397-426.
2. Dean DA, Strong DD, Zimmer WE. Nuclear entry of non-viral vectors. Gene Therapy 2005; 12: 881-890.
3. Medina-Kauwe LK, Xie J, Hamm-Alvarez S. Intracellular trafficking of non-viral vectors. Gene Therapy 2005; 12: 1734-1751.
4. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23: 709-717.
5. Yu W, Pirollo KF, Rait A, Yu B, Xiang LM, Huang WQ et al. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Therapy 2004; 11: 1434-1440.
6. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004; 10: 3667-3677.
7. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23: 1002-1007.
8. Kaul G, Amiji M. Tumor-targeted gene delivery using poly (ethylene glycol)-modified gelatin nanoparticles: In vitro and in vivo studies. Pharm Res 2005; 22: 951-961.
9. Walker GF, Fella C, Pelisek J, Fahrmeir J, Boeckle S, Ogris M et al. Toward synthetic viruses: Endosomal pH-triggered deshielding of targeted polyplexes greatly enhances gene transfer in vitro and in vivo. Mol Ther 2005; 11: 418-425.
10. Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006; 13: 328-337.
11. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004; 32: E149.
12. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984-8992.
13. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56: 1649-1659.
14. Wu X, Gao H, Pasupathy S, Tan PH, Ooi LL, Hui KM. Systemic administration of naked DNA with targeting specificity to mammalian kidneys. Gene Therapy 2005; 12: 477-486.
15. Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 2006; 17: 117-124.
16. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. Tumor-targeted gene therapy: Strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Rel 2003; 91: 173-181.
17. Kaul G, Amiji M. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target 2004; 12: 585-591.
18. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11: 50-55.
19. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005; 102: 198-203.
20. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003; 9: 1009-1014.
21. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-178.
22. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-12182.
23. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-114.
24. Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis 2006; 193: 1650-1657.
25. Sellins K, Fradkin L, Liggitt D, Dow S. Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. Mol Ther 2005; 12: 451-459.
26. Liu F, Shollenberger LM, Huang L. Non-immunostimulatory nonviral vectors. FASEB J 2004; 18: 1779-1781.
27. Zhang JS, Liu F, Huang L. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 2005; 57: 689-698.
28. Zhang JS, Liu F, Conwell CC, Tan Y, Huang L. Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. Mol Ther 2006; 13: 429-437.
29. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23: 457-462.
30. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006; 13: 494-505.
31. O'Malley Jr BW, Li D, McQuone SJ, Ralston R. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: From bench top to bedside. Laryngoscope 2005; 115: 391-404.
32. Wells DJ. Gene therapy progress and prospects: Electroporation and other physical methods. Gene Therapy 2004; 11: 1363-1369.
33. Kolonin MG, Sun J, Do KA, Vidal CI, Ji Y, Baggerly KA et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006; 20: 979-981.
34. Lechardeur D, Verkman AS, Lukacs GL. Intracellular routing of plasmid DNA during non-viral gene transfer. Adv Drug Deliv Rev 2005; 57: 755-767.
35. Riu E, Grimm D, Huang Z, Kay MA. Increased maintenance and persistence of transgenes by excision of expression cassettes from plasmid sequences in vivo. Hum Gene Ther 2005; 16: 558-570.
36. Caldas H, Jaynes FO, Boyer MW, Hammond S, Altura RA. Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy. Mol Cancer Ther 2006; 5: 693-703.
37. Chu TC, Marks III JW, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD et al. Aptamer:tOxin conjugates that specifically target prostate tumor cells. Cancer Res 2006; 66: 5989-5992.
38. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006; 103: 6315-6320.
39. Pestourie C, Tavitian B, Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie 2005; 87: 921-930.